Ruth B Etzioni

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6781053/ruth-b-etzioni-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79 papers	5,038 citations	29 h-index	70 g-index
93 ext. papers	6,347 ext. citations	12.2 avg, IF	5.55 L-index

#	Paper	IF	Citations
79	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care.. *European Urology*, **2022**,	10.2	5
78	Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort.. *Annals of Internal Medicine*, **2022**,	8	11
77	Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas. *JAMA Health Forum*, **2022**, 3, e221116	2	0
76	Identifying Preferred Breast Cancer Risk Predictors: A Holistic Perspective. *Journal of the National Cancer Institute*, **2021**, 113, 660-661	9.7	0
75	Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer. *JNCI Cancer Spectrum*, **2021**, 5, pkaa098	4.6	4
74	Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries. *Cancer*, **2021**, 127, 2926-2933	6.4	1
73	Identifying breast cancer recurrence histories via patient-reported outcomes. *Journal of Cancer Survivorship*, **2021**, 1	5.1	1
72	The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. *Journal of the National Cancer Institute*, **2021**, 113, 1336-1342	9.7	6
71	Prostate Cancer Screening Guidelines for Black Men: Spotlight on an Empty Stage. *Journal of the National Cancer Institute*, **2021**, 113, 650-651	9.7	4
70	Impact of cancer screening on metastasis: A prostate cancer case study. *Journal of Medical Screening*, **2021**, 28, 480-487	1.4	
69	Multi-Cancer Early Detection: Learning from the past to Meet the Future. *Journal of the National Cancer Institute*, **2021**,	9.7	5
68	When to Discuss Prostate Cancer Screening With Average-Risk Men. *American Journal of Preventive Medicine*, **2021**, 61, 294-298	6.1	0
67	A Quantitative Framework to Study Potential Benefits and Harms of Multi-Cancer Early Detection Testing. *Cancer Epidemiology Biomarkers and Prevention*, **2021**,	4	2
66	Reconsidering the Trade-offs of Prostate Cancer Screening. *New England Journal of Medicine*, **2020**, 382, 2465-2468	59.2	25
65	Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer. *Journal of the National Cancer Institute*, **2020**, 112, 1013-1020	9.7	14
64	Strategizing Screening for Melanoma in an Era of Novel Treatments: A Model-Based Approach. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 2599-2607	4	1
63	Correction: Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study. *JMIR Cancer*, **2020**, 6, e23821	3.2	

62	Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study. *JMIR Cancer*, **2020**, 6, e18143	3.2	2
61	Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. *Ca-A Cancer Journal for Clinicians*, **2020**, 70, 321-346	220.7	162
60	Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels. *Journal of the National Cancer Institute*, **2020**, 112, 384-390	9.7	5
59	Definitive and sustained increase in prostate cancer metastases in the United States. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 988-990	2.8	3
58	A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. *PLoS ONE*, **2019**, 14, e0211918	3.7	5
57	Reply by Authors. *Journal of Urology*, **2019**, 202, 943	2.5	
56	Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication. *Journal of Urology*, **2019**, 202, 936-943	2.5	6
55	Cancer Outcomes in DCIS Patients Without Locoregional Treatment. *Journal of the National Cancer Institute*, **2019**, 111, 952-960	9.7	34
54	Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials. *American Journal of Epidemiology*, **2019**, 188, 197-205	3.8	9
53	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. *European Urology*, **2018**, 74, 211-217	10.2	22
52	Racial disparities in prostate cancer survival in a screened population: Reality versus artifact. *Cancer* , **2018**, 124, 1752-1759	6.4	7
51	Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study. *The Lancet Global Health*, **2018**, 6, e885-e893	13.6	34
50	Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. *Prostate*, **2018**, 78, 1077	4.2	
49	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. *Annals of Internal Medicine*, **2018**, 168, 1-9	8	25
48	The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. *Cancer*, **2018**, 124, 1197-1206	6.4	41
47	Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 1332-1341	4	17
46	Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *Ca-A Cancer Journal for Clinicians*, **2018**, 68, 250-281	220.7	759
45	Demographic changes in breast cancer incidence, stage at diagnosis and age associated with population-based mammographic screening. *Journal of Surgical Oncology*, **2017**, 115, 517-522	2.8	36

44	Is prostate cancer different in black men? Answers from 3 natural history models. *Cancer*, **2017**, 123, 2312-2319	6.4	57
43	Missteps in Current Estimates of Cancer Overdiagnosis. *Academic Radiology*, **2017**, 24, 226-229	4.3	7
42	Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 809-815	4	249
41	A Framework for Treatment Decision Making at Prostate Cancer Recurrence. *Medical Decision Making*, **2017**, 37, 905-913	2.5	6
40	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. *Annals of Internal Medicine*, **2017**, 167, 449-455	8	108
39	Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 222-227	4	26
38	Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies. *American Journal of Epidemiology*, **2016**, 184, 140-7	3.8	17
37	Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. *JAMA Oncology*, **2016**, 2, 890-8	13.4	39
36	Recent Trends in PSA Testing and Prostate Cancer Incidence: A Look at Context. *JAMA Oncology*, **2016**, 2, 955-6	13.4	18
35	Treatment Trends for Stage I Testicular Seminoma in an Equal-Access Medical System. *Clinical Genitourinary Cancer*, **2016**, 14, 438-443	3.3	4
34	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. *Nature Medicine*, **2016**, 22, 369-78	50.5	425
33	Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	26
32	Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer. *International Journal of Breast Cancer*, **2016**, 2016, 2182985	2.3	4
31	Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA Oncology*, **2015**, 1, 342-9	13.4	46
30	Effect of Screening Mammography on Cancer Incidence and Mortality. *JAMA Internal Medicine*, **2015**, 175, 1490-1	11.5	7
29	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. *European Urology*, **2015**, 68, 1083-8	19.2	39
28	Measures of survival benefit in cancer drug development and their limitations. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 122-7	2.8	4
27	Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. *JAMA - Journal of the American Medical Association*, **2015**, 314, 1599-614	27.4	904

26	National trends in the management of low and intermediate risk prostate cancer in the United States. *Journal of Urology*, **2015**, 193, 95-102	2.5	67
25	Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy. *Cancer*, **2015**, 121, 2465-73	6.4	43
24	Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 677-82	4	15
23	The diffusion of docetaxel in patients with metastatic prostate cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	12
22	Overdiagnosis and overtreatment of prostate cancer. *European Urology*, **2014**, 65, 1046-55	10.2	528
21	Expected population impacts of discontinued prostate-specific antigen screening. *Cancer*, **2014**, 120, 3519-26	6.4	60
20	A reality check for overdiagnosis estimates associated with breast cancer screening. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	35
19	Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. *Clinical Cancer Research*, **2014**, 20, 5302-10	12.9	15
18	Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality. *Journal of the National Cancer Institute Monographs*, **2013**, 2013, 117-23	4.8	5
17	Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence. *Medical Care*, **2013**, 51, 304-6	3.1	5
16	Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. *Medical Care*, **2013**, 51, 295-300	3.1	43
15	Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. *Annals of Internal Medicine*, **2013**, 158, 831-8	8	92
14	Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. *Annals of Internal Medicine*, **2013**, 158, 145-53	8	99
13	The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. *Cancer*, **2012**, 118, 5955-63	6.4	100
12	Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. *Clinical Cancer Research*, **2012**, 18, 6742-7	12.9	24
11	Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. *Biostatistics*, **2010**, 11, 707-19	3.7	38
10	Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. *Medical Decision Making*, **2008**, 28, 323-31	2.5	80
9	Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. *Biometrics*, **2008**, 64, 10-9	1.8	84

8	Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. *Cancer*, **2007**, 109, 1877-86	6.4	72
7	Case-control studies of the efficacy of cancer screening: overcoming bias from nonrandom patterns of screening. *Epidemiology*, **2004**, 15, 409-13	3.1	15
6	Combining biomarkers to detect disease with application to prostate cancer. *Biostatistics*, **2003**, 4, 523-38	3.7	75
5	Quality of life in survivors of colorectal carcinoma **2000**, 88, 1294-1303		233
4	Quality of life in survivors of colorectal carcinoma **2000**, 88, 1294		6
3	Estimating asymptomatic duration in cancer: the AIDS connection. *Statistics in Medicine*, **1997**, 16, 627-44	2.3	12
2	Statistical Methods for Analyzing Speedup Learning Experiments. *Machine Learning*, **1994**, 14, 333-347	4	2
1	Statistical methods for analyzing speedup learning experiments. *Machine Learning*, **1994**, 14, 333-347	4	11